VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
OSUROraSure Technologies, Inc.
$4.25$306M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

OSUR logoOraSure Technologies, Inc.(OSUR)Earnings, Financials & Key Ratios

OSUR•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryDiagnostics and life science tools
AboutOraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.Show more
  • Revenue$115M-38.1%
  • EBITDA-$58M-495.5%
  • Net Income-$69M-252.5%
  • EPS (Diluted)-0.94-261.5%
  • Gross Margin41.9%+2.2%
  • EBITDA Margin-50.37%-862.1%
  • Operating Margin-59.23%-434.3%
  • Net Margin-59.76%-469.4%
  • ROE-18.3%-294.6%

OSUR Key Insights

OraSure Technologies, Inc. (OSUR) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 89 (top 11%)
  • ✓Trading at only 0.9x book value

✗Weaknesses

  • ✗Profits declining 35.7% over 5 years
  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Sales declining 7.7% over 5 years
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when OSUR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

OSUR Price & Volume

OraSure Technologies, Inc. (OSUR) stock price & volume — 10-year historical chart

Loading chart...

OSUR Growth Metrics

OraSure Technologies, Inc. (OSUR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-0.4%
5 Years-7.7%
3 Years-33.29%
TTM-47.34%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-64.96%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-148.39%

Return on Capital

10 Years2.37%
5 Years-2.5%
3 Years-2.75%
Last Year-16.83%

OSUR Recent Earnings

OraSure Technologies, Inc. (OSUR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.32-39.1%
$0.23
Rev
$28M+0.8%
$28M
Q1 2026
Feb 25, 2026
Metric
Actual
Est
EPS
$0.19-11.8%
$0.17
Rev
$27M+1.0%
$26M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$0.13+18.8%
$0.16
Rev
$27M+2.4%
$26M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.19-26.7%
$0.15
Rev
$31,242-8.0%
$33,969
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.32vs $0.23-39.1%
$28Mvs $28M+0.8%
Q1 2026Feb 25, 2026
$0.19vs $0.17-11.8%
$27Mvs $26M+1.0%
Q4 2025Nov 5, 2025
$0.13vs $0.16+18.8%
$27Mvs $26M+2.4%
Q3 2025Aug 5, 2025
$0.19vs $0.15-26.7%
$31,242vs $33,969-8.0%
Based on last 12 quarters of dataView full earnings history →

OSUR Peer Comparison

OraSure Technologies, Inc. (OSUR) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
QDEL logoQDELQuidelOrtho CorporationDirect Competitor930.68M13.67-0.82-1.89%-45.57%-56.31%1.46
IDXX logoIDXXIDEXX Laboratories, Inc.Direct Competitor44.64B562.0942.9710.42%24.63%70.87%0.67
ABT logoABTAbbott LaboratoriesProduct Competitor153.68B88.3811.574.59%31.88%27.26%0.32
BDX logoBDXBecton, Dickinson and CompanyProduct Competitor52.16B143.9824.708.23%5.33%4.54%0.76
HOLX logoHOLXHologic, Inc.Product Competitor16.97B76.0130.531.74%13.18%11.01%0.52
NEOG logoNEOGNeogen CorporationProduct Competitor2.03B9.31-1.85-3.2%-68.47%-28.64%0.44
CLOV logoCLOVClover Health Investments, Corp.Product Competitor2.59B5.00-29.4140.34%-2.58%-17.08%
TMO logoTMOThermo Fisher Scientific Inc.Supply Chain172.66B464.6126.193.91%15.18%13.23%0.76

Compare OSUR vs Peers

OraSure Technologies, Inc. (OSUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs QDEL

Most directly comparable listed peer for OSUR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare OSUR against a more recognizable public peer.

Peer Set

Compare Top 5

vs QDEL, IDXX, ABT, BDX

OSUR Income Statement

OraSure Technologies, Inc. (OSUR) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
167.06M181.74M154.6M171.72M233.67M387.48M405.47M185.83M115.02M85.12M
Revenue Growth %
36.05%8.79%-14.93%11.07%36.08%65.82%4.64%-54.17%-38.1%-47.34%
Cost of Goods Sold
68.11M68.13M60.02M69.85M116.07M239.04M226.05M109.6M66.82M52.07M
COGS % of Revenue
40.77%37.49%38.82%40.68%49.67%61.69%55.75%58.98%58.1%-
Gross Profit
98.96M▲ 0%
113.61M▲ 14.8%
94.58M▼ 16.7%
101.87M▲ 7.7%
117.6M▲ 15.4%
148.44M▲ 26.2%
179.42M▲ 20.9%
76.23M▼ 57.5%
48.2M▼ 36.8%
33.04M▲ 0%
Gross Margin %
59.23%62.51%61.18%59.32%50.33%38.31%44.25%41.02%41.9%38.82%
Gross Profit Growth %
19.76%14.81%-16.75%7.7%15.44%26.22%20.87%-57.52%-36.77%-
Operating Expenses
71.22M74.35M85.59M107.75M129.25M153.68M125.34M96.83M116.32M82.93M
OpEx % of Revenue
42.63%40.91%55.36%62.75%55.31%39.66%30.91%52.11%101.13%-
Selling, General & Admin
57.85M58.1M65.96M76.72M95.08M117.44M92.18M72.41M73.79M51.07M
SG&A % of Revenue
34.63%31.97%42.66%44.68%40.69%30.31%22.73%38.96%64.16%-
Research & Development
13.37M16.25M19.63M31.03M34.17M36.24M33.16M24.42M42.53M31.86M
R&D % of Revenue
8%8.94%12.7%18.07%14.62%9.35%8.18%13.14%36.97%-
Other Operating Expenses
0000000000
Operating Income
27.74M▲ 0%
39.27M▲ 41.6%
9M▼ 77.1%
-5.88M▼ 165.4%
-11.65M▼ 98.0%
-5.24M▲ 55.0%
54.08M▲ 1131.5%
-20.6M▼ 138.1%
-68.12M▼ 230.7%
-49.88M▲ 0%
Operating Margin %
16.6%21.61%5.82%-3.43%-4.99%-1.35%13.34%-11.09%-59.23%-58.6%
Operating Income Growth %
86.6%41.56%-77.09%-165.4%-98.01%54.99%1131.45%-138.09%-230.7%-
EBITDA
34.14M45.72M16.34M3.5M9K8.76M73.98M-9.73M-57.93M-42.5M
EBITDA Margin %
20.44%25.15%10.57%2.04%0%2.26%18.25%-5.24%-50.37%-49.93%
EBITDA Growth %
66.12%33.91%-64.27%-78.55%-99.74%97200%744.8%-113.15%-495.52%-57.72%
D&A (Non-Cash Add-back)
6.4M6.45M7.34M9.39M11.66M14M19.9M10.87M10.19M7.38M
EBIT
27.74M39.27M9M-5.88M-11.65M-5.24M54.08M-20.6M-66.93M-52.11M
Net Interest Income
0000000000
Interest Income
0000000000
Interest Expense
0000000000
Other Income/Expense
13.29M-7.55M12.34M2.36M2.36M-10.43M2.18M2.9M1.19M-573.54K
Pretax Income
41.03M▲ 0%
31.72M▼ 22.7%
21.33M▼ 32.7%
-3.52M▼ 116.5%
-9.29M▼ 163.7%
-15.68M▼ 68.7%
56.26M▲ 458.9%
-17.7M▼ 131.5%
-66.93M▼ 278.1%
-50.46M▲ 0%
Pretax Margin %
24.56%17.45%13.8%-2.05%-3.98%-4.05%13.87%-9.53%-58.19%-59.28%
Income Tax
10.08M11.32M4.67M11.4M13.71M1.46M2.6M1.8M1.8M2.26M
Effective Tax Rate %
24.58%35.69%21.92%-323.44%-147.5%-9.3%4.63%-10.16%-2.69%-4.47%
Net Income
30.95M▲ 0%
20.4M▼ 34.1%
16.66M▼ 18.3%
-14.92M▼ 189.6%
-23M▼ 54.1%
-17.13M▲ 25.5%
53.66M▲ 413.2%
-19.5M▼ 136.3%
-68.73M▼ 252.5%
-52.71M▲ 0%
Net Margin %
18.52%11.22%10.77%-8.69%-9.84%-4.42%13.23%-10.49%-59.76%-61.93%
Net Income Growth %
56.94%-34.1%-18.34%-189.59%-54.12%25.5%413.17%-136.34%-252.47%-64.96%
Net Income (Continuing)
30.95M20.4M16.66M-14.92M-23M-17.13M53.66M-19.5M-68.73M-52.71M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
0.51▲ 0%
0.33▼ 35.3%
0.27▼ 18.2%
-0.22▼ 181.5%
-0.32▼ 45.5%
-0.25▲ 21.9%
0.72▲ 388.0%
-0.26▼ 136.1%
-0.94▼ 261.5%
-0.76▲ 0%
EPS Growth %
45.71%-35.29%-18.18%-181.48%-45.45%21.88%388%-136.11%-261.54%-148.39%
EPS (Basic)
0.520.330.27-0.22-0.32-0.250.73-0.26-0.94-
Diluted Shares Outstanding
61.02M62.53M62.17M67.5M71.98M72.5M74.39M74.43M73.48M69.67M
Basic Shares Outstanding
59.05M61.11M61.67M67.5M71.98M72.5M73.35M74.43M73.48M69.67M
Dividend Payout Ratio
----------

OSUR Balance Sheet

OraSure Technologies, Inc. (OSUR) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
221.91M219.31M224.55M288.89M299.31M325.19M386.46M333.22M261.91M240.78M
Cash & Short-Term Investments
155.9M156.57M156.34M209.4M153.04M110.85M290.41M267.76M199.28K176.96M
Cash Only
72.87M88.44M75.72M160.8M116.76M83.98M290.41M267.76M199.28K176.96M
Short-Term Investments
83.03M68.13M80.62M48.6M36.28M26.87M0000
Accounts Receivable
42.52M34.84M36.95M38.84M45.32M70.8M40.17M23.82M22.2K24.81M
Days Sales Outstanding
92.969.9787.2382.5570.7966.6936.1646.780.07104.21
Inventory
19.34M22.89M23.16M31.86M53.14M95.7M47.61M34.2M31.06K30.31M
Days Inventory Outstanding
103.66122.62140.81166.49167.09146.1376.88113.890.17224.55
Other Current Assets
4.33M3.08M5.68M4.93M39.87M41.57M2.23M3.49M261.66M8.7M
Total Non-Current Assets
74.3M96.26M124.75M165.58M161.68M118.99M96.39M146.44M141.26M138.39M
Property, Plant & Equipment
21.37M24.3M37.29M57.63M84.98M71.11M58.27M58.69M39.18K37.86M
Fixed Asset Turnover
7.82x7.48x4.15x2.98x2.75x5.45x6.96x3.17x2935.78x1.72x
Goodwill
20.08M18.52M36.2M40.35M40.28M35.1M35.7M40.33M43.36K43.05M
Intangible Assets
8.22M5.14M14.67M17.9M14.34M11.69M1.21M17.43M19.05K18.94M
Long-Term Investments
20.69M44.75M33.42M47.72M17.01M0028.3M25.96M104.4M
Other Non-Current Assets
1.98M3.55M3.16M1.97M5.07M1.09M1.22M1.53M115.2M13.68M
Total Assets
296.2M▲ 0%
315.57M▲ 6.5%
349.3M▲ 10.7%
454.47M▲ 30.1%
460.99M▲ 1.4%
444.18M▼ 3.6%
482.85M▲ 8.7%
479.66M▼ 0.7%
403.17M▼ 15.9%
379.17M▲ 0%
Asset Turnover
0.56x0.58x0.44x0.38x0.51x0.87x0.84x0.39x0.29x0.21x
Asset Growth %
42.45%6.54%10.69%30.11%1.43%-3.65%8.7%-0.66%-15.95%-46.49%
Total Current Liabilities
32.24M27.98M32.71M46.49M68.06M69.06M39.54M33.48M39.8M44.08M
Accounts Payable
10.23M10.6M9.57M17.41M28.02M38.02M13.15M8.17M6.52K10.63M
Days Payables Outstanding
54.8156.7858.1890.9688.1258.0521.2327.220.0452.37
Short-Term Debt
000000002.23M2.22M
Deferred Revenue (Current)
1.31M3.52M3.71M4.81M2.94M2.27M1.56M2.96M1.52K6.71M
Other Current Liabilities
4.96M3.49M8.93M4.48M4.75M5.52M3.98M5.22M37.56M30.37M
Current Ratio
6.88x7.84x6.86x6.21x4.40x4.71x9.77x9.95x6.58x5.46x
Quick Ratio
6.28x7.02x6.16x5.53x3.62x3.32x8.57x8.93x6.58x4.77x
Cash Conversion Cycle
141.75135.82169.86158.08149.77154.7791.81133.450.2276.38
Total Non-Current Liabilities
5.88M4.21M9.44M9.41M12.39M10.69M12.64M35.84M22.55M21.76M
Long-Term Debt
0000000010.97M0
Capital Lease Obligations
005.58M4.49M9.15M9.6M11.39M12.43M034.3M
Deferred Tax Liabilities
1.95M3.31M899K1.2M2.23M408K554K000
Other Non-Current Liabilities
3.93M02.96M3.73M1M680K696K23.4M11.58M21.76M
Total Liabilities
38.12M32.19M42.15M55.9M80.46M79.75M52.17M69.32M62.34M65.84M
Total Debt
007.22M6.13M12.27M12.55M13.5M14.6M13.2M12.66M
Net Debt
-72.87M-88.44M-68.49M-154.67M-104.49M-71.43M-276.9M-253.16M13M-176.96M
Debt / Equity
--0.02x0.02x0.03x0.03x0.03x0.04x0.04x0.04x
Debt / EBITDA
--0.44x1.75x1363.78x1.43x0.18x---0.30x
Net Debt / EBITDA
-2.13x-1.93x-4.19x-44.14x-11609.78x-8.16x-3.74x--4.16x
Interest Coverage
----------
Total Equity
258.08M▲ 0%
283.38M▲ 9.8%
307.14M▲ 8.4%
398.57M▲ 29.8%
380.53M▼ 4.5%
364.43M▼ 4.2%
430.67M▲ 18.2%
410.34M▼ 4.7%
340.83M▼ 16.9%
313.32M▲ 0%
Equity Growth %
38.87%9.8%8.39%29.77%-4.53%-4.23%18.18%-4.72%-16.94%-63.41%
Book Value per Share
4.234.534.945.905.295.035.795.514.644.50
Total Shareholders' Equity
258.08M283.38M307.14M398.57M380.53M364.43M430.67M410.34M340.83M313.32M
Common Stock
0000000000
Retained Earnings
-119.51M-99.19M-82.53M-97.45M-120.45M-137.59M-83.93M-103.43M-172.16M-194.54M
Treasury Stock
0000000000
Accumulated OCI
-10.34M-18.71M-12.14M-9.1M-10.08M-18.43M-14.94M-24.36M-18.4M-20.04M
Minority Interest
0000000000

OSUR Cash Flow Statement

OraSure Technologies, Inc. (OSUR) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
28.16M39.09M9.8M5.81M-35.38M-47.2M141.58M27.37M-49.02K-43.19M
Operating CF Margin %
16.85%21.51%6.34%3.38%-15.14%-12.18%34.92%14.73%-0.04%-
Operating CF Growth %
23.67%38.83%-74.92%-40.77%-709.3%-33.41%399.95%-80.67%-100.18%-8733.37%
Net Income
30.95M20.4M16.66M-14.92M-23M-17.93M53.66M-19.5M-68.73K-52.71M
Depreciation & Amortization
6.4M7.22M7.73M9.71M12.49M15.54M20.94M10.87M10.19K9.95M
Stock-Based Compensation
6.97M15.24M4.06M7.14M7.81M11.62M10.73M11.92M10.15K8.69M
Deferred Taxes
-649K-919K-1.46M-392K1.03M-1.65M102K-657K-103-439.63K
Other Non-Cash Items
131K-400K-8.28M-424K4.72M15.79M10.4M5.92M6.8M5.6M
Working Capital Changes
-15.65M-2.45M-8.9M4.69M-38.44M-70.56M45.76M18.82M-6.8M4.85M
Change in Receivables
-22.12M6.63M-2.21M-2.32M-6.45M-25.16M31.12M15.87M1.95M-3.08M
Change in Inventory
-7.39M-3.86M-1.04M-8.61M-27.94M-43.05M48.23M13.1M3.56M5.76M
Change in Payables
5.16M208K-1.54M7.38M3.23M3.96M-26.98M-7.58M-1.72M3.11M
Cash from Investing
-96.35M-17.43M-19.8M-14.03M-5.5M21.09M66.15M-39.03M-6.81K-8.09M
Capital Expenditures
-4.34M-6.34M-9.31M-28.92M-48.12M-63.91M-10.3M-3.8M-4.2K-4.19M
CapEx % of Revenue
2.6%3.49%6.02%16.84%20.59%16.49%2.54%2.04%0%4.92%
Acquisitions
00-11.8M-3.04M0121K0-5.04M-3.61K-3.61K
Investments
----------
Other Investing
-92.02M-11.08M0351K513K60.33M48.67M-30M1K-3.9M
Cash from Financing
30.43M-1.89M-4.68M92.48M-2.82M-3.83M-3.02M-4.18M-16.94K-22.27M
Debt Issued (Net)
00-1.17M-687K-686K-1.38M-1.34M-842K-61K-49K
Equity Issued (Net)
-1.24M-3.59M-3.71M92.95M-2.11M-2.25M-1.9M-3.55M-15.04M-19.1M
Dividends Paid
0000000000
Share Repurchases
-1.24M-3.59M-3.71M-2.09M-2.11M-2.25M-1.9M-3.55M-15.04M-19.1M
Other Financing
31.68M1.7M196K218K-18K-193K223K214K15.08M-3.13M
Net Change in Cash
-36.92M▲ 0%
15.57M▲ 142.2%
-12.72M▼ 181.7%
85.09M▲ 768.8%
-44.04M▼ 151.8%
-32.78M▲ 25.6%
206.43M▲ 729.7%
-22.64M▼ 111.0%
-68.48K▲ 99.7%
-70.61M▲ 0%
Free Cash Flow
23.82M▲ 0%
32.75M▲ 37.5%
490K▼ 98.5%
-23.12M▼ 4817.8%
-83.5M▼ 261.2%
-111.11M▼ 33.1%
131.28M▲ 218.2%
23.58M▼ 82.0%
-53.22K▼ 100.2%
-47.88M▲ 0%
FCF Margin %
14.26%18.02%0.32%-13.46%-35.73%-28.68%32.38%12.69%-0.05%-56.25%
FCF Growth %
29.35%37.48%-98.5%-4817.76%-261.2%-33.07%218.15%-82.04%-100.23%-2657.78%
FCF per Share
0.390.520.01-0.34-1.16-1.531.760.32-0.00-0.69
FCF Conversion (FCF/Net Income)
0.91x1.92x0.59x-0.39x1.54x2.76x2.64x-1.40x0.00x0.91x
Interest Paid
0000000000
Taxes Paid
000000000786K

OSUR Key Ratios

OraSure Technologies, Inc. (OSUR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
13.94%7.53%5.64%-4.23%-5.9%-4.6%13.5%-4.64%-18.3%-15.09%
Return on Invested Capital (ROIC)
15.92%15.49%3.11%-1.83%-3.36%-1.38%18.16%-9.94%-20%-24.02%
Gross Margin
59.23%62.51%61.18%59.32%50.33%38.31%44.25%41.02%41.9%38.82%
Net Margin
18.52%11.22%10.77%-8.69%-9.84%-4.42%13.23%-10.49%-59.76%-61.93%
Debt / Equity
--0.02x0.02x0.03x0.03x0.03x0.04x0.04x0.04x
FCF Conversion
0.91x1.92x0.59x-0.39x1.54x2.76x2.64x-1.40x0.00x0.91x
Revenue Growth
36.05%8.79%-14.93%11.07%36.08%65.82%4.64%-54.17%-38.1%-47.34%
Related:OSUR Dividend History·OSUR Revenue History·OSUR Price History·OSUR P/E History·OSUR Financial Ratios·OSUR Institutional Holders

OSUR SEC Filings & Documents

OraSure Technologies, Inc. (OSUR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Apr 17, 2026·SEC

Material company update

Mar 30, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 9, 2026·SEC

FY 2025

Mar 7, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 8, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

OSUR Frequently Asked Questions

OraSure Technologies, Inc. (OSUR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

OraSure Technologies, Inc. (OSUR) reported $85.1M in revenue for fiscal year 2025. This represents a 24% increase from $68.7M in 1996.

OraSure Technologies, Inc. (OSUR) saw revenue decline by 38.1% over the past year.

OraSure Technologies, Inc. (OSUR) reported a net loss of $52.7M for fiscal year 2025.

Dividend & Returns

OraSure Technologies, Inc. (OSUR) has a return on equity (ROE) of -18.3%. Negative ROE indicates the company is unprofitable.

OraSure Technologies, Inc. (OSUR) had negative free cash flow of $47.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in OSUR back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

How much would $100/month in OSUR be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →